TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16712936

Group type: EXPERIMENTAL
Intervention: 2-ethylhexanol at 1.5 ppm
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 2-ethylhexanol at 10 ppm
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 2-ethylhexanol at 20 ppm
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Variable concentrations of 2-ethylhexanol over 4 hours
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Constant concentrations of 2-ethylhexanol
Number of subjects: 46
Study: 15031611

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg (E20)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg (L10)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: All treatments (E20, L10, P)
Number of subjects: 703
Study: 11180494

Group type: EXPERIMENTAL
Intervention: Bright light therapy combined with placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bright light therapy combined with melatonin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9663225

Group type: EXPERIMENTAL
Intervention: Adjunctive subconjunctival mitomycin C (MMC) during primary glaucoma triple procedure
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Adjunctive subconjunctival mitomycin C (MMC) for 3 minutes
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (no adjunctive mitomycin C)
Number of subjects: 174
Study: 7829176

Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen, administered 6 times at 15 minute intervals 90 minutes preoperatively in addition to the routine dilation regimen.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no flurbiprofen treatment).
Number of subjects: 60
Study: 3278412

Group type: EXPERIMENTAL
Intervention: CDP-choline (1,000 mg/day i.v. once daily for 14 days)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 272
Study: 31230026

Group type: EXPERIMENTAL
Intervention: 6-month supervised training courses (weekly gym training and Taiji sessions), followed by a free 6-month unsupervised use of exercise facilities, and unsupervised low-cost exercise for another 12 months
Number of subjects: 914

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 914
Study: 29151036

Group type: EXPERIMENTAL
Intervention: Initial combination therapy (losartan 50-100 mg plus hydrochlorothiazide 12.5-25 mg)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Initial monotherapy (losartan 50-100 mg or hydrochlorothiazide 12.5-25 mg)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Combination therapy (losartan 100 mg and hydrochlorothiazide 12.5 to 25 mg) in phase 2
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Amlodipine with or without doxazosin in phase 3
Number of subjects: 605
Study: 25591555

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 210
Study: 23166203

Group type: COMPARATOR
Intervention: Combined-exercise training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 40
Study: 21604900

Group type: EXPERIMENTAL
Intervention: 40-session short-term dynamic psychotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: 40-session cognitive treatment
Number of subjects: 50
Study: 18836622

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 134

Group type: COMPARATOR
Intervention: Meperidine/midazolam
Number of subjects: 134
Study: 16441968

Group type: EXPERIMENTAL
Intervention: Bipolar dissection
Number of subjects: 245

Group type: COMPARATOR
Intervention: Cold dissection
Number of subjects: 245
Study: 12544441

Group type: EXPERIMENTAL
Intervention: 0.9% alcohol beer
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual alcohol intake
Number of subjects: 16
Study: 11685784

Group type: EXPERIMENTAL
Intervention: Mailed guidelines plus educational outreach visits from community pharmacists
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mailed guidelines only
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Educational outreach visits
Number of subjects: 20
Study: 9713471

Group type: EXPERIMENTAL
Intervention: CDDP‐MS containing 200 mg of cisplatin (n = 5)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CDDP‐S containing 100 mg of cisplatin (n = 10)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CDDP‐MS
Number of subjects: 15
Study: 8148215

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) 600 mg single dose followed by 300 mg thrice daily for 3 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) 300 mg thrice daily for 3 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) as add-on therapy
Number of subjects: 43
Study: 2454440

Group type: EXPERIMENTAL
Intervention: Opioids (morphine or equivalent doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30529378

Group type: EXPERIMENTAL
Intervention: Crestal implants (placed approximately 2 mm below the bone crest)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Subcrestal implants (placed at bone crest level)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 128
Study: 28279602

Group type: EXPERIMENTAL
Intervention: Chymotrypsin combined with gentamicin via interventional sialendoscopy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Gentamicin alone
Number of subjects: 104
Study: 26814466

Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite (SH1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite (SH2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 10% Ricinus communis (RC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 0.85% saline (C)
Number of subjects: 64
Study: 22925498

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-9 group (4 weekly instillations of 40 mg followed by 5 monthly instillations)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-12 group (12 instillations of 40 mg every 2 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 21107600

Group type: EXPERIMENTAL
Intervention: Constant-load exercise test at 50% delta (Δ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Constant-load exercise test at 70% delta (Δ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RPE regressed against proportion of time
Number of subjects: 20
Study: 19933888

Group type: EXPERIMENTAL
Intervention: Simulated auditory hallucinations experience
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison group (50 students)
Number of subjects: 150
Study: 16506061

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (6 mg)
Number of subjects: 10
Study: 15585783

Group type: EXPERIMENTAL
Intervention: Short-chain fructooligosaccharides (10 g/d)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Soybean oligosaccharides (10 g/d)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides (10 g/d)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Type III resistant starch (10 g/d)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: NDCHs (2.5, 5.0, 7.5, or 10 g/d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 11760223

Group type: EXPERIMENTAL
Intervention: Nelfinavir suspension (1250 mg in 100 mL of water)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nelfinavir tablets (five 250-mg tablets)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nelfinavir suspension
Number of subjects: 12
Study: 9088601

Group type: EXPERIMENTAL
Intervention: 19-mm elliptical extra broad light guide
Number of subjects: 30

Group type: COMPARATOR
Intervention: 11-mm standard light guide
Number of subjects: 30
Study: 8463441

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3811814

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (30 mg i.v. bolus followed by 1 mg/min for 8 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study: 30209589

Group type: EXPERIMENTAL
Intervention: GM.CD40L
Number of subjects: 65

Group type: COMPARATOR
Intervention: GM.CD40L.CCL21
Number of subjects: 65
Study: 26846333

Group type: EXPERIMENTAL
Intervention: Roxadustat (1.5 to 2.0 mg/kg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Roxadustat (2.0 mg/kg)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 144
Study: 23160813

Group type: EXPERIMENTAL
Intervention: Power-holders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subordinates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutrals
Number of subjects: 0
Study: 22539656

Group type: EXPERIMENTAL
Intervention: High physical workload at baseline
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: High physical workload
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Not being obese
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 385
Study: 20211908

Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17963858

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (RING) releasing 15 mcg ethinyl estradiol and 120 mcg etonogestrel per day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low-dose oral contraceptive (PILL) containing 20 mcg ethinyl estradiol and 100 mcg levonorgestrel daily
Number of subjects: 65
Study: 15859575

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11940128

Group type: EXPERIMENTAL
Intervention: Nurse-led counselling service for inflammatory bowel disease patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study: 10365352

Group type: EXPERIMENTAL
Intervention: Twice weekly supervised oral iron administration (group B)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Daily unsupervised oral iron administration (group A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Parenteral iron (group C)
Number of subjects: 51
Study: 10547247

Group type: EXPERIMENTAL
Intervention: Low-lactose formula (LLF, <5% lactose)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Lactose-containing formula (LCF, 24 kcal/oz)
Number of subjects: 306
Study: 2070978

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation
Number of subjects: 91
Study: 6622049

Group type: EXPERIMENTAL
Intervention: Fine-bore suprapubic catheterisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent urethral catheterisation
Number of subjects: 0
Study: 30499221

Group type: EXPERIMENTAL
Intervention: qRF‐MRF method
Number of subjects: 5
Study: 29806281

Group type: EXPERIMENTAL
Intervention: New anatomical locking plate for sternoclavicular joint (Group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Distal radial T locking plate internal fixation (Group B)
Number of subjects: 32
Study: 26773735

Group type: EXPERIMENTAL
Intervention: Standard treatment for standard-risk ALL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensified consolidation study arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger age at diagnosis
Number of subjects: 0
Study: 25547786

Group type: EXPERIMENTAL
Intervention: Levofloxacin-based triple therapy (LAL): levofloxacin 500 mg daily, amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Moxifloxacin-based triple therapy (MAL): moxifloxacin 400 mg daily, amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Number of subjects: 306

Group type: COMPARATOR
Intervention: Standard treatment (CAL): clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d.
Number of subjects: 306
Study: 22763344

Group type: EXPERIMENTAL
Intervention: Multi-channel NIRS with CoG approach during hand movements
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Multi-channel NIRS with CoG approach during foot movements
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Multi-channel NIRS with CoG approach during rhythmic or discrete hand or foot tapping
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Multi-channel NIRS with CoG approach for OHb responses
Number of subjects: 13
Study: 20135347

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 500

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: High VEGFR2 expression
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: EGFR expression and EGFR gene copy number
Number of subjects: 500
Study: 18768772

Group type: EXPERIMENTAL
Intervention: Increasing word reading ability in 15 at-risk children
Number of subjects: 60

Group type: COMPARATOR
Intervention: Skilled readers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unskilled readers
Number of subjects: 60
Study: 15995436

Group type: EXPERIMENTAL
Intervention: Alumina ceramic bearings
Number of subjects: 316

Group type: COMPARATOR
Intervention: Cobalt chrome-on-polyethylene bearings (Control)
Number of subjects: 316
Study: 12207812

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 30
Study: 10489096

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 8942326

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 82
Study: 1680982

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional therapy (hydralazine + sorbitrate)
Number of subjects: 120
Study: 6210726

Group type: EXPERIMENTAL
Intervention: fenoterol 100 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: fenoterol 200 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: fenoterol 50 micrograms combined with 20 micrograms of ipratropium
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: fenoterol 100 micrograms combined with 40 micrograms of ipratropium
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 micrograms of ipratropium
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31096990

Group type: EXPERIMENTAL
Intervention: Patient-specific drill template (PDT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Freehand group
Number of subjects: 10
Study: 28183355

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) - 2000 pulses of 1‐Hz TMS for 10 consecutive business days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 35
Study: 26530645

Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (XLPE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moderately cross-linked then annealed polyethylene
Number of subjects: 100
Study: 23422463

Group type: EXPERIMENTAL
Intervention: Virtual reality-based cognitive rehabilitation program (12 sessions)
Number of subjects: 37
Study: 21157365

Group type: COMPARATOR
Intervention: 23 mm cryoballoon
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 28 mm cryoballoon
Number of subjects: 8
Study: 19824225

Group type: EXPERIMENTAL
Intervention: Intensive early intervention programme (OPUS)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study: 17542352

Group type: EXPERIMENTAL
Intervention: Generic oral solution of risperidone (1 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Risperdal tablets (1 mg)
Number of subjects: 32
Study: 15356547

Group type: EXPERIMENTAL
Intervention: Exposure to tobacco smoke (measured by urinary cotinine)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Symptoms of asthma
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Nighttime asthma symptoms
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Allergen sensitization (measured by skin prick test)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Medication treatment for asthma
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Overall asthma control
Number of subjects: 368
Study: 12297482

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with 20 g/d L-arginine for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard parenteral nutrition
Number of subjects: 40
Study: 9708936

Group type: EXPERIMENTAL
Intervention: Chemotherapy supported with G‐CSF (5 microg/kg subcutaneously on Days 2‐13; Arm B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemotherapy alone (Arm A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chemotherapy supported with G‐CSF (Arm B)
Number of subjects: 80
Study: 8110580

Group type: EXPERIMENTAL
Intervention: Bilateral ilioinguinal nerve block
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Wound infiltration with 0.5% bupivacaine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no local anaesthetic supplementation)
Number of subjects: 62
Study: 1710099

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid 5-hydroxyindoleacetic acid levels in long-term weight-restored anorectic subjects
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid homovanillic acid levels in long-term weight-restored anorectic subjects
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cerebrospinal fluid 5-hydroxyindoleacetic acid levels in controls
Number of subjects: 32
Study: 10249189

Group type: EXPERIMENTAL
Intervention: Empathy training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 0
Study: 31448382

Group type: EXPERIMENTAL
Intervention: Live Artemia nauplii + 0‰ salinity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Live Artemia nauplii + 2‰ salinity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Frozen Artemia nauplii + 0‰ salinity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Frozen Artemia nauplii + 2‰ salinity
Number of subjects: 5
Study: 30487231

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 28236469

Group type: EXPERIMENTAL
Intervention: Grass allergen peptide 8x6Q2W
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 26542494

Group type: EXPERIMENTAL
Intervention: Impella 2.5 (registry patients)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Impella 2.5 (PROTECT II trial patients)
Number of subjects: 637
Study: 23820174

Group type: EXPERIMENTAL
Intervention: Recombinant FXIII 17.5 IU/kg
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Recombinant FXIII 35 IU/kg
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 22688890

Group type: EXPERIMENTAL
Intervention: HRV-biofeedback (12 sessions)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Craving-control (no intervention)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-craving-control (no intervention)
Number of subjects: 56
Study: 19481229

Group type: EXPERIMENTAL
Intervention: Red wine (118 mL daily for 6 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: White wine (118 mL daily for 6 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no wine)
Number of subjects: 24
Study: 17532935

Group type: EXPERIMENTAL
Intervention: Lung-volume reduction surgery
Number of subjects: 23
Study: 15592949

Group type: EXPERIMENTAL
Intervention: PSA measurement (n = 3,562, group 1)
Number of subjects: 7124

Group type: COMPARATOR
Intervention: Control group (n = 3,562, group 2)
Number of subjects: 7124
Study: 11310304

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) with a single burst (8 or 16 stimuli)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cardioversion (defibrillation threshold plus 10 J)
Number of subjects: 20
Study: 9599103

Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 1915

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 1915
Study: 7974677

Group type: EXPERIMENTAL
Intervention: 7.5 mg chlorproguanil daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 100 mg proguanil daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 50 mg chlorproguanil weekly
Number of subjects: 156

Group type: COMPARATOR
Intervention: 100 mg calcium lactate weekly (placebo)
Number of subjects: 156
Study: 2686567

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 31

Group type: COMPARATOR
Intervention: Modified Toupet semifundoplication
Number of subjects: 31
Study: 409052

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate 10 mg, four times a day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31860534

Group type: EXPERIMENTAL
Intervention: L-Citrulline (CIT) 6 g·d for 7 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: L-Citrulline (CIT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Maltodextrin placebo (PLAC)
Number of subjects: 9
Study: 30971596

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion at 15 mg/kg/h
Number of subjects: 122

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 122
Study: 28814398

Group type: EXPERIMENTAL
Intervention: MedDiet + EVOO
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: MedDiet + nuts
Number of subjects: 983

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 983
Study: 25704049

Group type: EXPERIMENTAL
Intervention: Needle guide-assisted (NG) technique
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional freehand (FH) technique
Number of subjects: 36